Australian cochlear implant maker highlights promising reception of its Nucleus Nexa System and strategic cost-cutting, but faces ongoing challenges in key markets and margins, impacting near-term growth prospects.
Cochlear has used its latest earnings update to underline both the promise of its new flagship implant platform and the pressure it is still facing across key markets. The Australian medical device maker said the Nucleus Nexa System was well received after launch and helped deliver an average price rise of about 3%, but that was not enough to offset softer overall trading, with constant-currency sales growth of only 2% and underlying net profit of A$322 million.
The company’s latest platform is central to its push for higher-value sales and future upgrades. Cochlear said the system, which was first introduced in 2025 and later received regulatory clearance in the United States, uses upgradeable firmware and internal memory to allow recipients to access future improvements without replacing the implant. In May, the company also launched the technology in Korea, where it highlighted onboard diagnostics and a new internal chipset.
Chief executive Diggory Howitt said the launch had exceeded internal expectations, with adoption above 95% in developed markets. He also said the move had helped the company test pricing power after several years without a material increase at that level. Still, Cochlear’s operating backdrop remained mixed, with developed-market implant revenue rising only 1% and Western Europe down 8% because of healthcare system strain, including long NHS waiting lists, industrial action in Spain and lost share in Germany.
The weakest point was the United States, where Cochlear said insurance pre-authorisation delays and broader economic caution were slowing patient decisions. Howitt said the company was seeing growth in referrals and surgeries through clinics with established networks and through its direct-to-consumer programmes, but the self-navigated channel was less reliable. He said Cochlear-supported surgeries in the US rose 10%, while referrals from the hearing-aid channel were flat year on year.
Cochlear is also trying to widen its long-term growth runway beyond the current implant cycle. The company said services revenue rose 6% in constant currency, helped by the retirement of the Nucleus 7 processor and stronger marketing of the Nucleus 8. It said cost-cutting measures had trimmed fixed costs as a share of revenue by 2 percentage points, with around A$40 million of annualised benefit expected from FY27. But margin pressure remains evident: gross margin fell to 71% and the company booked a A$109 million fair value loss on investments, largely tied to its holding in Epiminder. Cochlear expects only low-single-digit revenue growth in FY27 and said it sees a slow recovery ahead, with Middle East instability still weighing on visibility.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
